Title : Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

Pub. Date : 2015 Dec 16

PMID : 26673577

1 Functional Relationships(s)
Compound Name
Protein Name
1 nab-paclitaxel-based regimens (with gemcitabine or carboplatin+-bevacizumab) also demonstrated efficacy and safety in first-line phase II trials of human epidermal growth factor receptor 2-negative metastatic breast cancer. nab erb-b2 receptor tyrosine kinase 2 Homo sapiens